Skip to main content

Table 4 Correlation between serum level of the three biomarkers and clinicopathological characteristics in GC patients

From: A novel strategy to identify candidate diagnostic and prognostic biomarkers for gastric cancer

Characteristics AGT level SERPINH1 level MMP7 level Score 1 level Score 2 level
Low (n = 66) High (n = 66) P-value Low (n = 66) High (n = 66) P-value Low (n = 66) High (n = 66) P-value Low (n = 66) High (n = 66) P-value Low (n = 66) High (n = 66) P-value
Gender
 Male 45 45 1.00 49 41 0.135 47 43 0.455 49 41 0.135 51 38 0.196
 Female 21 21   17 25   19 23   17 25   19 23  
Age (years)
 ≤ 65 37 42 0.375 41 38 0.594 40 39 0.859 41 38 0.594 42 36 0.909
 > 65 29 24   25 28   26 27   25 28   28 25  
Tumor size (cm)
 ≤ 4 47 30 0.003 42 35 0.217 46 31 0.008 42 35 0.217 50 27 0.002
 > 4 19 36   24 31   20 35   24 31   20 34  
Tumor invasion
 T1–T2 26 15 0.039 27 14 0.014 27 14 0.014 27 14 0.014 30 11 0.002
 T3–T4 40 51   39 52   39 52   39 52   40 50  
Lymph node invasion
 Negative 27 22 0.368 27 22 0.368 27 22 0.368 27 22 0.368 30 19 0.167
 Positive 39 44   39 44   39 44   39 44   40 42  
Metastasis
 Negative 57 54 0.475 58 53 0.234 59 52 0.096 58 53 0.234 63 47 0.044
 Positive 9 12   8 13   7 14   8 13   7 14  
TNM stage
 I–II 38 24 0.015 40 22 0.002 38 24 0.015 40 22 0.002 42 20 0.002
 III–IV 28 42   26 44   28 42   26 44   28 41  
  1. Score 1 =  (0.180 × concentration of AGT) +  (0.544 × concentration of SERPINH1) +  (0.135 × concentration of MMP7), patients were divided into a high-risk group and a low-risk group according to the median of score 1
  2. Score 2, two or more of the three proteins are high-expressed, the patients were divided into a high-risk group; otherwise, the patients were divided into a low-risk group